The Mosaico Study, also known as HVTN 706/HPX3002, is a multi-country HIV vaccine study testing whether an investigational HIV vaccine regimen can prevent HIV acquisition in cisgender men and transgender persons who have sex with cisgender men and/or transgender persons. The study is being conducted in Argentina, Brazil, Italy, Mexico, Peru, Poland, Puerto Rico, Spain, and the United States. As of September 10, 2021, the study reached full enrollment of 3,800 participants. The communities and research teams involved in this study are hard at work to find an answer to the scientific questions about safety, immune response, comfortability with injections, and efficacy of the vaccine regimen. Answers to these questions are expected in 2024.

More information about the Mosaico study can be found at www.mosaicostudy.com.  By: Dr. Stephaun Wallace, HVTN Core, Seattle, WA, USA Dr. Stephaun Wallace is the Director of External Relations for the HVTN and directs community engagement